Japanese clinical practice guidelines for prostate cancer 2023
International Journal of Urology · 2024-11 · 31 (11) · 1180-1222
DOI: 10.1111/iju.15545 ↗Kurz gefasst
Leitlinie in der Zeitschrift International Journal of Urology, online erschienen am 30.07.2024. Verfasst von Yasuo Kohjimoto und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Wakayama Medical University, Wakayama, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 166 Literaturangaben.
Abstract (Originalsprache)
This fourth edition of the Japanese Clinical Practice Guidelines for Prostate Cancer 2023 is compiled. It was revised under the leadership of the Japanese Urological Association, with members selected from multiple academic societies and related organizations (Japan Radiological Society, Japanese Society for Radiation Oncology, the Department of EBM and guidelines, Japan Council for Quality Health Care (Minds), Japanese Society of Pathology, and the patient group (NPO Prostate Cancer Patients Association)), in accordance with the Minds Manual for Guideline Development (2020 ver. 3.0). The most important feature of this revision is the adoption of systematic reviews (SRs) in determining recommendations for 14 clinical questions (CQs). Qualitative SRs for these questions were conducted, and the final recommendations were made based on the results through the votes of 24 members of the guideline development group. Five algorithms based on these results were also created. Contents not covered by the SRs, which are considered textbook material, have been described in the general statement. In the general statement, a literature search for 14 areas was conducted; then, based on the general statement and CQs of the Japanese Clinical Practice Guidelines for Prostate Cancer 2016, the findings revealed after the 2016 guidelines were mainly described. This article provides an overview of these guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, Wakayama Medical University, Wakayama, Japan.
- Department of Urology and Renal Transplantation, Yokohama City University Medical Center, Yokohama, Kanagawa, Japan.
- Department of Hepato-Biliary-Pancreatic and Gastrointestinal Surgery, School of Medicine, International University of Health and Welfare, Narita, Chiba, Japan.
- Department of EBM and Guidelines, Japan Council for Quality Health Care (Minds), Tokyo, Japan.
- Department of Biostatistics and Data Management, Sapporo Medical University School of Medicine, Sapporo, Japan.
- Department of Urology, Nihon University School of Medicine, Tokyo, Japan.
ORCID-Profile: Satoru Takahashi, Mikio Sugimoto, Hitoshi Ishikawa, Takashi Mizowaki, Nobuaki Matsubara, Osamu Ukimura, Isao Hara
Zitieren
APA
Kohjimoto, Y., Uemura, H., Yoshida, M., Hinotsu, S., Takahashi, S., Takeuchi, T., Suzuki, K., Shinmoto, H., Tamada, T., Inoue, T., Sugimoto, M., Takenaka, A., Habuchi, T., Ishikawa, H., Mizowaki, T., Saito, S., Miyake, H., Matsubara, N., Nonomura, N., …, & Hara, I. (2024). Japanese clinical practice guidelines for prostate cancer 2023. International Journal of Urology, 31(11), 1180-1222. https://doi.org/10.1111/iju.15545
Vancouver
Kohjimoto Y, Uemura H, Yoshida M, Hinotsu S, Takahashi S, Takeuchi T, et al. Japanese clinical practice guidelines for prostate cancer 2023. International Journal of Urology. 2024;31(11):1180-1222. doi:10.1111/iju.15545
BibTeX
@article{Kohjimoto2024,
author = {Kohjimoto, Yasuo and Uemura, Hiroji and Yoshida, Masahiro and Hinotsu, Shiro and Takahashi, Satoru and Takeuchi, Tsutomu and Suzuki, Kazuhiro and Shinmoto, Hiroshi and Tamada, Tsutomu and Inoue, Takahiro and Sugimoto, Mikio and Takenaka, Atsushi and Habuchi, Tomonori and Ishikawa, Hitoshi and Mizowaki, Takashi and Saito, Shiro and Miyake, Hideaki and Matsubara, Nobuaki and Nonomura, Norio and Sakai, Hideki and Ito, Akihiro and Ukimura, Osamu and Matsuyama, Hideyasu and Hara, Isao},
title = {Japanese clinical practice guidelines for prostate cancer 2023},
journal = {International Journal of Urology},
year = {2024},
volume = {31},
number = {11},
pages = {1180--1222},
doi = {10.1111/iju.15545}
}
EUVIMED